<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38970055</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.</ArticleTitle><Pagination><StartPage>630</StartPage><MedlinePgn>630</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">630</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-024-05412-3</ELocationID><Abstract><AbstractText>Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomatology with Post-COVID Syndrome (PCS). Despite the severity of symptoms and various neurological, cardiovascular, microvascular, and skeletal muscular findings, no biomarkers have been identified. The Transient receptor potential melastatin 3 (TRPM3) channel, involved in pain transduction, thermosensation, transmitter and neuropeptide release, mechanoregulation, vasorelaxation, and immune defense, shows altered function in ME/CFS. Dysfunction of TRPM3 in natural killer (NK) cells, characterized by reduced calcium flux, has been observed in ME/CFS and PCS patients, suggesting a role in ineffective pathogen clearance and potential virus persistence and autoimmunity development. TRPM3 dysfunction in NK cells can be improved by naltrexone in vitro and ex vivo, which may explain the moderate clinical efficacy of low-dose naltrexone (LDN) treatment. We propose that TRPM3 dysfunction may have a broader involvement in ME/CFS pathophysiology, affecting other organs. This paper discusses TRPM3's expression in various organs and its potential impact on ME/CFS symptoms, with a focus on small nerve fibers and the brain, where TRPM3 is involved in presynaptic GABA release.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xf6;hn</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4120-3544</Identifier><AffiliationInfo><Affiliation>Institute for General Pharmacology and Toxicology, University Hospital, Goethe University, Frankfurt am Main, Germany. loehn@em.uni-frankfurt.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirth</LastName><ForeName>Klaus Josef</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Institute for General Pharmacology and Toxicology, University Hospital, Goethe University, Frankfurt am Main, Germany. klaus@mitodicure.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mitodicure GmbH, D-65830, Kriftel, Germany. klaus@mitodicure.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050053">TRPM Cation Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>5S6W795CQM</RegistryNumber><NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475667">TRPM3 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050053" MajorTopicYN="Y">TRPM Cation Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009271" MajorTopicYN="Y">Naltrexone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Exercise intolerance</Keyword><Keyword MajorTopicYN="N">GABA</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">ME/CFS</Keyword><Keyword MajorTopicYN="N">Myalgic Encephalomyelitis/Chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">Naltrexone</Keyword><Keyword MajorTopicYN="N">Post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">Small fiber neuropathy</Keyword><Keyword MajorTopicYN="N">TRPM3 channel</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>6</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>6</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38970055</ArticleId><ArticleId IdType="pmc">PMC11227206</ArticleId><ArticleId IdType="doi">10.1186/s12967-024-05412-3</ArticleId><ArticleId IdType="pii">10.1186/s12967-024-05412-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dixit NM, Churchill A, Nsair A, Hsu JJ, Post-Acute COVID-19 syndrome and the cardiovascular system: what is known? Am Heart J Plus. 2021;5:100025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8223036</ArticleId><ArticleId IdType="pubmed">34192289</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. 2022;32(4):e2315. doi: 10.1002/rmv.2315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2315</ArticleId><ArticleId IdType="pubmed">34888989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth KJ, Lohn M. Orthostatic Intolerance after COVID-19 infection: is disturbed Microcirculation of the Vasa Vasorum of Capacitance vessels the primary defect? Med (Kaunas). 2022;58(12).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9788017</ArticleId><ArticleId IdType="pubmed">36557009</ArticleId></ArticleIdList></Reference><Reference><Citation>Blitshteyn S, Brinth L, Hendrickson JE, Martinez-Lavin M. Autonomic dysfunction and HPV immunization: an overview. Immunol Res. 2018;66(6):744&#x2013;54. doi: 10.1007/s12026-018-9036-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-018-9036-1</ArticleId><ArticleId IdType="pubmed">30478703</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front Immunol. 2022;13:981532. doi: 10.3389/fimmu.2022.981532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.981532</ArticleId><ArticleId IdType="pmc">PMC9552223</ArticleId><ArticleId IdType="pubmed">36238301</ArticleId></ArticleIdList></Reference><Reference><Citation>Legler F, Meyer-Arndt L, Modl L, Kedor C, Freitag H, Stein E, et al. Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort. EClinicalMedicine. 2023;63:102146. doi: 10.1016/j.eclinm.2023.102146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102146</ArticleId><ArticleId IdType="pmc">PMC10469383</ArticleId><ArticleId IdType="pubmed">37662515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Balinas C, Eaton-Fitch N, Staines D, Marshall-Gradisnik S. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from chronic fatigue Syndrome/ myalgic encephalomyelitis patients. Mol Med. 2019;25(1):14. doi: 10.1186/s10020-019-0083-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-019-0083-4</ArticleId><ArticleId IdType="pmc">PMC6480905</ArticleId><ArticleId IdType="pubmed">31014226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Eaton N, Balinas C, Staines D, Marshall-Gradisnik S. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from chronic fatigue Syndrome/Myalgic encephalomyelitis patients. Mol Med. 2018;24(1):44. doi: 10.1186/s10020-018-0046-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-018-0046-1</ArticleId><ArticleId IdType="pmc">PMC6092868</ArticleId><ArticleId IdType="pubmed">30134818</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. Potential therapeutic benefit of low dose naltrexone in myalgic Encephalomyelitis/Chronic fatigue syndrome: role of Transient Receptor Potential Melastatin 3 Ion channels in pathophysiology and treatment. Front Immunol. 2021;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8313851</ArticleId><ArticleId IdType="pubmed">34326841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel function in natural killer cells from myalgic Encephalomyelitis/Chronic fatigue syndrome patients. Front Immunol. 2019;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6834647</ArticleId><ArticleId IdType="pubmed">31736966</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton-Fitch N, Cabanas H, du Preez S, Staines D, Marshall-Gradisnik S. The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients. J Translational Med. 2021;19(1):306. doi: 10.1186/s12967-021-02974-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-02974-4</ArticleId><ArticleId IdType="pmc">PMC8281618</ArticleId><ArticleId IdType="pubmed">34266470</ArticleId></ArticleIdList></Reference><Reference><Citation>Magawa CT, Eaton-Fitch N, Balinas C, Sasso EM, Thapaliya K, Barnden L et al. Identification of transient receptor potential melastatin 3 proteotypic peptides employing an efficient membrane protein extraction method for natural killer cells. Front Physiol. 2022;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9540229</ArticleId><ArticleId IdType="pubmed">36213251</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T, Johnston S, Clarke L, Smith P, Staines D, Marshall-Gradisnik S. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. Clin Exp Immunol. 2017;187(2):284&#x2013;93. doi: 10.1111/cei.12882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12882</ArticleId><ArticleId IdType="pmc">PMC5217865</ArticleId><ArticleId IdType="pubmed">27727448</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T, Staines D, Nilius B, Smith P, Marshall-Gradisnik S. Novel identification and characterisation of transient receptor potential melastatin 3 ion channels on natural killer cells and B lymphocytes: effects on cell signalling in chronic fatigue syndrome/Myalgic encephalomyelitis patients. Biol Res. 2016;49(1):27. doi: 10.1186/s40659-016-0087-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40659-016-0087-2</ArticleId><ArticleId IdType="pmc">PMC4888729</ArticleId><ArticleId IdType="pubmed">27245705</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasso EM, Muraki K, Eaton-Fitch N, Smith P, Lesslar OL, Deed G, et al. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients. Mol Med. 2022;28(1):98. doi: 10.1186/s10020-022-00528-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-022-00528-y</ArticleId><ArticleId IdType="pmc">PMC9388968</ArticleId><ArticleId IdType="pubmed">35986236</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton-Fitch N, Du Preez S, Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. J Translational Med. 2022;20(1):94. doi: 10.1186/s12967-022-03297-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03297-8</ArticleId><ArticleId IdType="pmc">PMC8848670</ArticleId><ArticleId IdType="pubmed">35172836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Rohacs T. The newest TRP channelopathy: Gain of function TRPM3 mutations cause epilepsy and intellectual disability. Channels (Austin) 2021;15(1):386&#x2013;97. doi: 10.1080/19336950.2021.1908781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19336950.2021.1908781</ArticleId><ArticleId IdType="pmc">PMC8057083</ArticleId><ArticleId IdType="pubmed">33853504</ArticleId></ArticleIdList></Reference><Reference><Citation>Burglen L, Van Hoeymissen E, Qebibo L, Barth M, Belnap N, Boschann F et al. Gain-of-function variants in the ion channel gene TRPM3 underlie a spectrum of neurodevelopmental disorders. Elife. 2023;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9886277</ArticleId><ArticleId IdType="pubmed">36648066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TM, Mackay DS, Siegfried CJ, Shiels A. Mutation of the melastatin-related cation channel, TRPM3, underlies inherited cataract and glaucoma. PLoS ONE. 2014;9(8):e104000. doi: 10.1371/journal.pone.0104000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104000</ArticleId><ArticleId IdType="pmc">PMC4121231</ArticleId><ArticleId IdType="pubmed">25090642</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Yudin Y, Rohacs T. Disease-associated mutations in the human TRPM3 render the channel overactive via two distinct mechanisms. Elife. 2020;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255801</ArticleId><ArticleId IdType="pubmed">32343227</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm C, Kraft R, Sauerbruch S, Schultz G, Harteneck C. Molecular and functional characterization of the melastatin-related cation channel TRPM3. J Biol Chem. 2003;278(24):21493&#x2013;501. doi: 10.1074/jbc.M300945200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M300945200</ArticleId><ArticleId IdType="pubmed">12672799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Chen J, Sun L, Wu S, Gray KR, Rich A, et al. Expression and Characterization of Human Transient Receptor Potential Melastatin 3 (hTRPM3) *. J Biol Chem. 2003;278(23):20890&#x2013;7. doi: 10.1074/jbc.M211232200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M211232200</ArticleId><ArticleId IdType="pubmed">12672827</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiel G, M&#xfc;ller I, R&#xf6;ssler OG. Signal transduction via TRPM3 channels in pancreatic &#x3b2;-cells. J Mol Endocrinol. 2013;50(3):R75&#x2013;83. doi: 10.1530/JME-12-0237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JME-12-0237</ArticleId><ArticleId IdType="pubmed">23511953</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman HA, Chen A, Kravatz NL, Chavan SS, Chang EH. Involvement of neural transient receptor potential channels in peripheral inflammation. Front Immunol. 2020;11:590261. doi: 10.3389/fimmu.2020.590261.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.590261</ArticleId><ArticleId IdType="pmc">PMC7645044</ArticleId><ArticleId IdType="pubmed">33193423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Chen J, Sun L, Wu S, Gray KR, Rich A, et al. Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3) J Biol Chem. 2003;278(23):20890&#x2013;7. doi: 10.1074/jbc.M211232200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M211232200</ArticleId><ArticleId IdType="pubmed">12672827</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberwinkler J, Lis A, Giehl KM, Flockerzi V, Philipp SE. Alternative splicing switches the Divalent Cation selectivity of TRPM3 channels *. J Biol Chem. 2005;280(23):22540&#x2013;8. doi: 10.1074/jbc.M503092200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M503092200</ArticleId><ArticleId IdType="pubmed">15824111</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriens J, Owsianik G, Hofmann T, Philipp Stephan E, Stab J, Chen X, et al. TRPM3 is a Nociceptor Channel Involved in the detection of noxious heat. Neuron. 2011;70(3):482&#x2013;94. doi: 10.1016/j.neuron.2011.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.02.051</ArticleId><ArticleId IdType="pubmed">21555074</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberwinkler J, Philipp SE. TRPM3. In: Nilius B, Flockerzi V, editors. Mammalian transient receptor potential (TRP) cation channels: volume I. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. pp. 427&#x2013;59.</Citation></Reference><Reference><Citation>Zhang M, Ma Y, Ye X, Zhang N, Pan L, Wang B. TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases. Signal Transduct Target Ther. 2023;8(1):261. doi: 10.1038/s41392-023-01464-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01464-x</ArticleId><ArticleId IdType="pmc">PMC10319900</ArticleId><ArticleId IdType="pubmed">37402746</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten DK, Schultz BG, Berlau DJ. The Safety and Efficacy of Low-Dose Naltrexone in the management of Chronic Pain and inflammation in multiple sclerosis, Fibromyalgia, Crohn&#x2019;s Disease, and other Chronic Pain disorders. Pharmacotherapy. 2018;38(3):382&#x2013;9. doi: 10.1002/phar.2086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.2086</ArticleId><ArticleId IdType="pubmed">29377216</ArticleId></ArticleIdList></Reference><Reference><Citation>Toljan K, Vrooman B. Low-dose naltrexone (LDN)-Review of therapeutic utilization. Med Sci (Basel). 2018;6(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6313374</ArticleId><ArticleId IdType="pubmed">30248938</ArticleId></ArticleIdList></Reference><Reference><Citation>Isman A, Nyquist A, Strecker B, Harinath G, Lee V, Zhang X, et al. Low-dose naltrexone and NAD&#x2009;+&#x2009;for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav Immun Health. 2024;36:100733. doi: 10.1016/j.bbih.2024.100733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2024.100733</ArticleId><ArticleId IdType="pmc">PMC10862402</ArticleId><ArticleId IdType="pubmed">38352659</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485. doi: 10.1016/j.bbih.2022.100485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>Oaklander AL, Nolano M. Scientific advances in and clinical approaches to small-Fiber polyneuropathy: a review. JAMA Neurol. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10021074</ArticleId><ArticleId IdType="pubmed">31498378</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams RMC, Simpson DM, Navis A, Jette N, Zhou L, Shin SC. Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve. 2022;65(4):440&#x2013;3. doi: 10.1002/mus.27458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27458</ArticleId><ArticleId IdType="pmc">PMC8661991</ArticleId><ArticleId IdType="pubmed">34766365</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph P, Arevalo C, Oliveira RKF, Faria-Urbina M, Felsenstein D, Oaklander AL, et al. Insights from Invasive Cardiopulmonary Exercise Testing of patients with myalgic Encephalomyelitis/Chronic fatigue syndrome. Chest. 2021;160(2):642&#x2013;51. doi: 10.1016/j.chest.2021.01.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.01.082</ArticleId><ArticleId IdType="pmc">PMC8727854</ArticleId><ArticleId IdType="pubmed">33577778</ArticleId></ArticleIdList></Reference><Reference><Citation>Oaklander AL, Mills AJ, Kelley M, Toran LS, Smith B, Dalakas MC et al. Peripheral neuropathy evaluations of patients with prolonged long COVID. Neurol Neuroimmunol Neuroinflamm. 2022;9(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889896</ArticleId><ArticleId IdType="pubmed">35232750</ArticleId></ArticleIdList></Reference><Reference><Citation>Held K, Kichko T, De Clercq K, Klaassen H, Van Bree R, Vanherck J-C, et al. Activation of TRPM3 by a potent synthetic ligand reveals a role in peptide release. Proc Natl Acad Sci. 2015;112(11):E1363&#x2013;72. doi: 10.1073/pnas.1419845112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1419845112</ArticleId><ArticleId IdType="pmc">PMC4371942</ArticleId><ArticleId IdType="pubmed">25733887</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Carbajo L, Alpizar YA, Startek JB, L&#xf3;pez-L&#xf3;pez JR, P&#xe9;rez-Garc&#xed;a MT, Talavera K. Activation of the cation channel TRPM3 in perivascular nerves induces vasodilation of resistance arteries. J Mol Cell Cardiol. 2019;129:219&#x2013;30. doi: 10.1016/j.yjmcc.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2019.03.003</ArticleId><ArticleId IdType="pubmed">30853321</ArticleId></ArticleIdList></Reference><Reference><Citation>Azcue N, Del Pino R, Acera M, Fern&#xe1;ndez-Valle T, Ayo-Mentxakatorre N, P&#xe9;rez-Concha T, et al. Dysautonomia and small fiber neuropathy in post-COVID condition and chronic fatigue syndrome. J Translational Med. 2023;21(1):814. doi: 10.1186/s12967-023-04678-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04678-3</ArticleId><ArticleId IdType="pmc">PMC10648633</ArticleId><ArticleId IdType="pubmed">37968647</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriens J, Voets T. Sensing the heat with TRPM3. Pfl&#xfc;gers Archiv. Eur J Physiol. 2018;470(5):799&#x2013;807. doi: 10.1007/s00424-017-2100-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-017-2100-1</ArticleId><ArticleId IdType="pmc">PMC5942355</ArticleId><ArticleId IdType="pubmed">29305649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelemen B, Pinto S, Kim N, Lisztes E, Hanyicska M, Vlad&#xe1;r A, et al. The TRPM3 ion channel mediates nociception but not itch evoked by endogenous pruritogenic mediators. Biochem Pharmacol. 2021;183:114310. doi: 10.1016/j.bcp.2020.114310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2020.114310</ArticleId><ArticleId IdType="pmc">PMC8086171</ArticleId><ArticleId IdType="pubmed">33130130</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriens J, Voets T. Heat sensing involves a TRiPlet of ion channels. Br J Pharmacol. 2019;176(20):3893&#x2013;8. doi: 10.1111/bph.14812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14812</ArticleId><ArticleId IdType="pmc">PMC6811738</ArticleId><ArticleId IdType="pubmed">31372975</ArticleId></ArticleIdList></Reference><Reference><Citation>Held K, Toth BI. TRPM3 in brain (patho)physiology. Front Cell Dev Biol. 2021;9:635659. doi: 10.3389/fcell.2021.635659.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.635659</ArticleId><ArticleId IdType="pmc">PMC7959729</ArticleId><ArticleId IdType="pubmed">33732703</ArticleId></ArticleIdList></Reference><Reference><Citation>Seljeset S, Liebowitz S, Bright DP, Smart TG. Pre- and postsynaptic modulation of hippocampal inhibitory synaptic transmission by pregnenolone sulphate. Neuropharmacology. 2023;233:109530. doi: 10.1016/j.neuropharm.2023.109530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2023.109530</ArticleId><ArticleId IdType="pubmed">37037282</ArticleId></ArticleIdList></Reference><Reference><Citation>Thapaliya K, Marshall-Gradisnik S, Eaton-Fitch N, Eftekhari Z, Inderyas M, Barnden L. Imbalanced Brain neurochemicals in long COVID and ME/CFS: a preliminary study using MRI. Am J Med. 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">38588934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall PA, Ayaz H, Meng G, Hudson A, Sakib MN, Quah ACK, et al. Neurocognitive and psychiatric symptoms following infection with COVID-19: evidence from laboratory and population studies. Brain Behav Immun Health. 2023;28:100595. doi: 10.1016/j.bbih.2023.100595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2023.100595</ArticleId><ArticleId IdType="pmc">PMC9870612</ArticleId><ArticleId IdType="pubmed">36713476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hingorani KS, Bhadola S, Cervantes-Arslanian AM. COVID-19 and the brain. Trends Cardiovasc Med. 2022;32(6):323&#x2013;30. doi: 10.1016/j.tcm.2022.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2022.04.004</ArticleId><ArticleId IdType="pmc">PMC9022395</ArticleId><ArticleId IdType="pubmed">35461991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth KJ, Scheibenbogen C, Paul F. An attempt to explain the neurological symptoms of myalgic Encephalomyelitis/Chronic fatigue syndrome. J Transl Med. 2021;19(1):471. doi: 10.1186/s12967-021-03143-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-03143-3</ArticleId><ArticleId IdType="pmc">PMC8607226</ArticleId><ArticleId IdType="pubmed">34809664</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;1:CD008922.</Citation><ArticleIdList><ArticleId IdType="pubmed">22258993</ArticleId></ArticleIdList></Reference><Reference><Citation>Peck J, Urits I, Crane J, McNally A, Noor N, Patel M, et al. Oral muscle relaxants for the Treatment of Chronic Pain Associated with cerebral palsy. Psychopharmacol Bull. 2020;50(4 Suppl 1):142&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901132</ArticleId><ArticleId IdType="pubmed">33633423</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg U, Kadefors R, Melin B, Palmerud G, Hassm&#xe9;n P, Engstr&#xf6;m M, et al. Psychophysiological stress and emg activity of the trapezius muscle. Int J Behav Med. 1994;1(4):354&#x2013;70. doi: 10.1207/s15327558ijbm0104_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1207/s15327558ijbm0104_5</ArticleId><ArticleId IdType="pubmed">16250795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth KJ, Scheibenbogen C. Dyspnea in Post-COVID Syndrome following mild Acute COVID-19 infections: potential causes and consequences for a Therapeutic Approach. Med (Kaunas). 2022;58(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8951558</ArticleId><ArticleId IdType="pubmed">35334595</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun. 2024;15(1):17. doi: 10.1038/s41467-023-44432-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44432-3</ArticleId><ArticleId IdType="pmc">PMC10766651</ArticleId><ArticleId IdType="pubmed">38177128</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizjak DA, Ohmayer B, Buhl JL, Schneider EM, Walther P, Calzia E et al. Functional and Morphological Differences of Muscle Mitochondria in chronic fatigue syndrome and Post-COVID syndrome. Int J Mol Sci. 2024;25(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10855807</ArticleId><ArticleId IdType="pubmed">38338957</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>